Zuranolone is the first oral drug for postpartum depression. What the trial showed

Zuranolone is the first pill approved specifically to treat postpartum depression; until its 2023 US clearance, the only drug approved for the condition was an intravenous infusion given in a health-care facility [s2]. In the pivotal SKYLARK trial, a 14-day course improved depression scores more than placebo by day 15 — a genuine effect, but a modest one, and one that comes with a boxed warning about impaired driving [s1][s3].

Postpartum depression is a major depressive episode arising in the weeks around childbirth, and it is common. The treatment question has never been whether it can be treated but whether it can be treated quickly, because the illness unfolds during the period a parent is caring for a newborn. Zuranolone is a neuroactive steroid that acts on GABA-A receptors; it was developed as a rapid-acting, short-course oral option rather than the weeks-to-effect profile of standard antidepressants [s1].

What the trial did

SKYLARK was a double-blind phase 3 trial that randomised 196 women with severe postpartum depression in a 1:1 ratio to zuranolone 50 mg once daily or placebo for 14 days [s1]. The enrolled women met diagnostic criteria for a major depressive episode whose symptoms began in the third trimester or within four weeks of delivery [s2]. The primary endpoint was the change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) at day 15 — the day after the course ended [s1]. Of those enrolled, 170 (86.7%) completed the 45-day study [s1].

What it found

Zuranolone beat placebo on the primary endpoint: a least-squares mean HAM-D improvement of 15.6 points versus 11.6, a between-group difference of 4.0 points (95% CI, 1.7 to 6.3) [s1]. Separation from placebo was also seen earlier, at day 3, and persisted at days 28 and 45 — after treatment had stopped [s1].

The most common side effects occurring in at least 10% of participants were somnolence, dizziness and sedation [s1]. The trial reported no loss of consciousness, no withdrawal symptoms, and no increase in suicidal thoughts or behaviour [s1].

How to read a four-point difference

The result clears the bar for statistical significance, and the early separation — by day 3 — is the clinically interesting part, because speed is the feature standard antidepressants lack. But a four-point HAM-D difference is modest, both arms improved substantially, and a large share of the measured improvement occurred in the placebo group too [s1]. The trial was also short and enrolled women with severe postpartum depression; it does not establish how the drug performs over longer follow-up, in milder disease, or against an active antidepressant comparator rather than placebo.

What the label requires

The FDA approved zuranolone, sold as Zurzuvae, on 4 August 2023 for postpartum depression in adults [s2][s3]. The prescribing information sets the dose at 50 mg once daily in the evening with a fatty meal for 14 days, reducible to 40 mg if central-nervous-system effects occur [s3]. The label permits the drug to be used on its own or as an add-on to an oral antidepressant, and sets a lower dose for people with severe liver or moderate-to-severe kidney impairment [s3] — positioning it as a short, defined course rather than a long-term medication.

The label's central safety instruction is a boxed warning: the drug impairs the ability to drive, and patients are told not to drive or operate machinery for at least 12 hours after each dose across the full 14-day course, and that they may not be able to judge their own impairment [s3]. That caution is not a footnote for a population of new parents, and it shapes how and when the drug can realistically be used.

What to watch

Whether real-world use reproduces the trial's benefit and tolerability outside a controlled study; longer-term data on relapse after the 14-day course; and how zuranolone is positioned against — or alongside — existing antidepressants and non-drug treatments, which remain first-line for most people. For the wider context on why detecting and treating perinatal depression early matters, see our coverage of perinatal depression and infant outcomes and of perinatal sleep disturbance.

This article describes trial results and regulatory labelling. It is not medical advice, and treatment decisions belong with a clinician who knows the individual case. Anyone in crisis should contact local emergency services or a crisis line.

Sources

1. Zuranolone for the Treatment of Postpartum Depression — American Journal of Psychiatry, 26 July 2023
2. FDA Approves First Oral Treatment for Postpartum Depression — U.S. Food and Drug Administration, 4 August 2023
3. Zurzuvae (zuranolone) prescribing information, NDA 217369 — U.S. Food and Drug Administration, 4 August 2023